Drugs / NIZ985
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04261439 | Feb 2020 → Dec 2023 | melanoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02452268 | May 2017 → Mar 2022 | metastatic malignant neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIZ985 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452268 ↗ |
| Action | Activate | “NIZ985, a recombinant heterodimeric IL-15 agonist” PMID 34799399 ↗ Nov 2021 |
| Modality | Protein / enzyme biologic | “NIZ985 is a recombinant heterodimer of physiologically active interleukin (IL-)15 and IL-15 receptor alpha.” PMID 34799399 ↗ Nov 2021 |
| Route | Subcutaneous | “subcutaneously administered NIZ985” NCT04261439 ↗ |